Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)

84.95 UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Crinetics Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More ↗

August 14, 2026

The drugmaker should significantly mitigate its most important risk as it develops new products.

Via The Motley Fool

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire? ↗

August 07, 2026

This risk is weighing on the stock.

Via The Motley Fool

Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday ↗

August 04, 2026

The company notched a pair of modest beats in its second quarter.

Via The Motley Fool

Crinetics Pharmaceuticals (NASDAQ:CRNX) Beats Q1 Expectations on Strong PALSONIFY Launch, Stock Slips After Hours ↗

May 07, 2026

Via Chartmill

Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target ↗

July 30, 2026

There are other reasons to pay attention to Viking Therapeutics.

Via The Motley Fool

Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching ↗

July 19, 2026

The biotech's diversification efforts continue.

Via The Motley Fool

Topics Intellectual Property

Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals ↗

July 14, 2026

Vertex's $10 billion acquisition may have spooked investors, given how rich it appeared to be.

Via The Motley Fool

Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy? ↗

July 13, 2026

Vertex Pharmaceuticals recently announced its largest-ever acquisition.

Via The Motley Fool

Is This Biotech Stock a Buy Near Its 52-Week High? ↗

July 10, 2026

It's been a volatile year for the company, but don't let that scare you away.

Via The Motley Fool

Why This Pharmaceutical Stock Jumped Close to 100% This Week ↗

July 10, 2026

It is getting acquired by a larger firm in the sector.

Via The Motley Fool

Topics Bonds

Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy? ↗

July 10, 2026

Additional blockbuster drugs may be on the horizon.

Via The Motley Fool

Topics Intellectual Property

On Thursday, there are stocks with unusual volume. Let's take a look. ↗

July 09, 2026

Via Chartmill

Here's How Much $1000 Invested In Crinetics Pharmaceuticals 5 Years Ago Would Be Worth Today ↗

July 08, 2026

Crinetics Pharmaceuticals (NASDAQ:CRNX) has outperformed the market over the past 5 years by 21.74% on an annualized basis producing an average annual return of 33.07%. Currently, Crinetics...

Via Benzinga

The trading volume of these stocks is deviating from the norm in today's session. ↗

July 08, 2026

Via Chartmill

Vertex’s Crinetics Deal Balances Growth with Integration Risk ↗

July 08, 2026

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis...

Via MarketBeat

Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It. ↗

July 08, 2026

This buy gives Vertex both a recently-commercialized drug, and a very strong lead candidate.

Via The Motley Fool

Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know. ↗

July 07, 2026

The drugmaker is paying up for a new growth engine. Is the price disciplined?

Via The Motley Fool

Topics Intellectual Property

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

July 07, 2026

Via Chartmill

Most active stocks in Tuesday's session ↗

July 07, 2026

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 07, 2026

Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion. Tvardi Therapeutics...

Via Benzinga

Top stock movements in today's session. ↗

July 07, 2026

Via Chartmill

The market is filled with gapping stocks in Tuesday's session. ↗

July 07, 2026

Via Chartmill

Discover the top movers in Tuesday's pre-market session. ↗

July 07, 2026

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 07, 2026

Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.4 billion. Bluejay...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 06, 2026

Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-market session. Crinetics Pharmaceuticals (NASDAQ:CRNX) stock moved upwards by 99.85% to $84.0. The...

Via Benzinga

Monday's after hours session: top gainers and losers ↗

July 06, 2026

Via Chartmill

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗

May 18, 2026

Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.

Via The Motley Fool

Topics ETFs Regulatory Compliance

Crinetics (CRNX) Q1 2026 Earnings Transcript ↗

May 08, 2026

Crinetics (CRNX) Q1 2026 Earnings Transcript

Via The Motley Fool

Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More ↗

March 27, 2026

This biotech specializing in endocrine therapies reported a notable insider sale as it advances clinical-stage drug candidates.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough ↗

March 13, 2026

This biotech specializes in therapies for neurological disorders, advancing a diverse pipeline through late-stage trials and collaborations.

Via The Motley Fool

Topics Regulatory Compliance

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.